Half Year 2023 Arecor Therapeutics PLC Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Edward Austin Thomason - Liberum Capital Limited, Research Division - Analyst : Edward Thomason from Liberum. I just wanted to actually ask about AT247. So you called out in the slide, you have a slide on it. But if you actually look at Slide 20 to your upcoming milestones, there's no mention of it at all. So the future plan for AT247, has future R&D be deprioritized? What's the update?

Question: Edward Austin Thomason - Liberum Capital Limited, Research Division - Analyst : So has that strategy been done as a proactive measure right from the beginning, you want to try and sell them together? Or has that been reacted to the reception post the data?

Question: Edward Austin Thomason - Liberum Capital Limited, Research Division - Analyst : And then a question just for Susan. Just about the cost base, where you feel it is at the moment? Do you think it's a little bit too heavy, too light still? Obviously, there's a big jump in SG&A expenses. Should we expect that level going forward? Just a bit of guidance there.

Question: Edward Austin Thomason - Liberum Capital Limited, Research Division - Analyst : Okay. So on an ongoing basis, we expect the fixed cost for SG&A to be relatively stable and then some variable cost coming through?

Question: Edward Austin Thomason - Liberum Capital Limited, Research Division - Analyst : Diabetes as a couple, you've got a new CBO on, does macro changes in the pump market, which you've alluded to? Do you think -- we ask you when and where, when and how much. Do you think the heat map of the deal is increasing when you see that the macro environment and companies are paying out a lot of money that your chances are that the value creation point is going to come sooner, perhaps we have in our models?

Question: Edward Austin Thomason - Liberum Capital Limited, Research Division - Analyst : And next one is on the biosimilar. Quite a lot of public -- in the public domain new versions of Stelara biosimilar potentially coming to the market via (inaudible) and Samsung. Now J&J has a history of delaying by paying the biosimilar company of. Is that a concern for you? If your partner gets such a payment to delay launch, will that impact the economics on that for you? Or will you get a slice of that? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 14, 2023 / 10:00AM, AREC.L - Half Year 2023 Arecor Therapeutics PLC Earnings Call

Question: Edward Austin Thomason - Liberum Capital Limited, Research Division - Analyst : And final one, Susan. In the press release, it was mentioned that the Ogluo growth in the U.S. was 36% quarter-on-quarter. It was just quite impressive. Is that the kind of rate, I know the different market space. So that the kind of rate we should be looking at, like a very high sort of teens, low 20s